166 related articles for article (PubMed ID: 12201834)
21. A human TSH-secreting adenoma: endocrine, biochemical and morphological studies. Evidence of somatostatin receptors by using quantitative autoradiography. Clinical and biological improvement by SMS 201-995 treatment.
Polak M; Bertherat J; Li JY; Kujas M; Le Dafniet M; Weizani H; Van Effenterre R; Epelbaum J; Turpin G
Acta Endocrinol (Copenh); 1991 Apr; 124(4):479-86. PubMed ID: 1851593
[TBL] [Abstract][Full Text] [Related]
22. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
23. Long term treatment of a thyrotropin-secreting microadenoma with somatostatin analogues.
Prieto-Tenreiro A; Díaz-Guardiola P
Arq Bras Endocrinol Metabol; 2010; 54(5):502-6. PubMed ID: 20694413
[TBL] [Abstract][Full Text] [Related]
24. [Monosymptomatic hyperthyroidism and TSH-producing adenoma: successful therapy with octreotide].
Mayinger B; Axelos D; Pavel M; Hahn EG; Hensen J
Dtsch Med Wochenschr; 1999 Jan; 124(4):73-8. PubMed ID: 10071603
[TBL] [Abstract][Full Text] [Related]
25. [Effect of long-term treatment with octreotide-lar in a TSH-secreting pituitary macroadenoma and secondary hyperthyroidism].
Del Monte P; Bernasconi D; Ruelle A; Marugo A; Marugo M; Torre R
Minerva Endocrinol; 2005 Jun; 30(2):95-9. PubMed ID: 15988405
[TBL] [Abstract][Full Text] [Related]
26. Octreotide LAR treatment throughout pregnancy in an acromegalic woman.
Fassnacht M; Capeller B; Arlt W; Steck T; Allolio B
Clin Endocrinol (Oxf); 2001 Sep; 55(3):411-5. PubMed ID: 11589686
[TBL] [Abstract][Full Text] [Related]
27. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
Yoenem A; Cakyr B; Azal O; Corakcy A; Kutlu M; Oezata M
Endocr Regul; 1999 Dec; 33(4):169-74. PubMed ID: 10700085
[TBL] [Abstract][Full Text] [Related]
28. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.
Gatto F; Barbieri F; Castelletti L; Arvigo M; Pattarozzi A; Annunziata F; Saveanu A; Minuto F; Castellan L; Zona G; Florio T; Ferone D
Pituitary; 2011 Jun; 14(2):141-7. PubMed ID: 21086053
[TBL] [Abstract][Full Text] [Related]
29. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.
Abe T; Lüdecke DK
Eur J Endocrinol; 2001 Aug; 145(2):137-45. PubMed ID: 11454508
[TBL] [Abstract][Full Text] [Related]
30. Pregnancy after bromocriptine-induced reduction of an extrasellar prolactin-secreting pituitary macroadenoma.
Goodman LA; Chang RJ
Obstet Gynecol; 1984 Sep; 64(3 Suppl):2S-7S. PubMed ID: 6433250
[TBL] [Abstract][Full Text] [Related]
31. [Response of thyrotropinoma to somatostatin analogues: report of a case].
García Lafuente N; Berná Gascón MT; Pujalte López E; Falcó Jover G; Domínguez Escribano JR
An Med Interna; 2001 Dec; 18(12):663. PubMed ID: 11852512
[No Abstract] [Full Text] [Related]
32. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
Iglesias P; Díez JJ
J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
[TBL] [Abstract][Full Text] [Related]
33. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK
Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
[TBL] [Abstract][Full Text] [Related]
34. Dissociated responsiveness of a growth hormone- and thyrotropin-secreting pituitary adenoma to octreotide-long-acting release therapy: the intriguing case of Mister B.
Curtò L; Ragonese M; Losa M; Trimarchi F; Cannavò S
J Endocrinol Invest; 2010 Mar; 33(3):204-5. PubMed ID: 19609104
[No Abstract] [Full Text] [Related]
35. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
[TBL] [Abstract][Full Text] [Related]
36. An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant.
Meas T; Sobngwi E; Vexiau P; Boudou P
Ann Endocrinol (Paris); 2006 Jun; 67(3):249-52. PubMed ID: 16840917
[TBL] [Abstract][Full Text] [Related]
37. Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.
Lindsay JR; Harding JA; Ellis PK; Sheridan B; Atkinson AB
Pituitary; 2003; 6(4):209-14. PubMed ID: 15237932
[TBL] [Abstract][Full Text] [Related]
38. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.
Chanson P; Weintraub BD; Harris AG
Ann Intern Med; 1993 Aug; 119(3):236-40. PubMed ID: 8323093
[TBL] [Abstract][Full Text] [Related]
39. Cure of a thyrotrophin (TSH)-secreting pituitary adenoma by medical therapy.
Fliers E; van Furth WR; Bisschop PH
Clin Endocrinol (Oxf); 2012 Nov; 77(5):788-90. PubMed ID: 22486560
[No Abstract] [Full Text] [Related]
40. Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas.
Colao A; Filippella M; Di Somma C; Manzi S; Rota F; Pivonello R; Gaccione M; De Rosa M; Lombardi G
Endocrine; 2003 Apr; 20(3):279-83. PubMed ID: 12721508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]